tiprankstipranks
Advertisement
Advertisement
Denali Therapeutics Secures $200 Million Royalty Funding
PremiumCompany AnnouncementsDenali Therapeutics Secures $200 Million Royalty Funding
9d ago
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
Premium
The Fly
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
14d ago
Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright
Premium
The Fly
Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright
14d ago
Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
PremiumRatingsDenali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
14d ago
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
Premium
Ratings
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
14d ago
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy
Premium
Company Announcements
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy
14d ago
Denali Therapeutics reports Q4 EPS (73c), consensus (75c)
PremiumThe FlyDenali Therapeutics reports Q4 EPS (73c), consensus (75c)
1M ago
Denali Therapeutics initiated with a Peer Perform at Wolfe Research
Premium
The Fly
Denali Therapeutics initiated with a Peer Perform at Wolfe Research
1M ago
Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
Premium
Ratings
Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100